Skip to main content
Sanofi logo

Sanofi — Investor Relations & Filings

Ticker · SAN ISIN · FR0000120578 LEI · 549300E9PC51EN656011 PA Manufacturing
Open in API
Filings indexed 4,405 across all filing types
Latest filing 2024-12-09 Regulatory Filings
Country FR France
Listing PA SAN

About Sanofi

https://www.sanofi.com/en/directory/

Sanofi is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and marketing of therapeutic solutions. The company's portfolio includes a wide range of medicines and vaccines designed to improve human health. Sanofi focuses on several key therapeutic areas, including immunology, oncology, rare diseases, neurology, and vaccines. Emphasizing a research-driven approach, the company increasingly utilizes artificial intelligence to innovate and accelerate the delivery of new treatments for patients worldwide. Sanofi is also a producer of active pharmaceutical ingredients.

Recent filings

Filing Released Lang Actions
Press Release: ASH: Sarclisa combinations demonstrated significant benefits in newly diagnosed multiple myeloma patients
Regulatory Filings Classification · 92% confidence The document is titled 'Press Release' and details new clinical data (IMROZ and GMMG-HD7 phase 3 studies) for the drug Sarclisa, presented at the American Society of Hematology (ASH) Annual Meeting. This content focuses on scientific results, clinical benefits, and future regulatory plans, which is characteristic of an announcement related to clinical trial outcomes or scientific findings. It is not a formal regulatory filing like a 10-K, a short announcement of a report (RPA), or a transcript of a call. Since the content is a detailed scientific/clinical update, it best fits the category for Investor Presentations (IP) or potentially a Regulatory Filing (RNS) if no better fit exists. Given the depth of data presentation, similar to what might be found in an Investor Presentation, but being a press release announcing data, it is most closely aligned with the type of material shared with investors to convey performance/pipeline updates. However, since it is a press release announcing clinical data, and not a formal presentation deck, the most appropriate general category for significant, non-standardized corporate/scientific updates that aren't formal reports or earnings releases is often 'Regulatory Filings' (RNS) or sometimes 'Investor Presentation' (IP) if it were structured as slides. Given the context of financial reporting databases, a press release detailing clinical trial results is often categorized broadly. Since it is not an ER, IR, or 10-K, and it's not explicitly a presentation deck (IP), RNS serves as the best fit for a significant, non-standard announcement of scientific progress that impacts investor outlook.
2024-12-09 English
Press Release: ASH: rilzabrutinib demonstrated significant patient benefit in the first positive phase 3 study of a BTK inhibitor in ITP
Earnings Release Classification · 99% confidence The document is explicitly titled 'Press Release' and details the positive results from the LUNA 3 phase 3 study of rilzabrutinib, including key efficacy and safety data, quotes from medical professionals and the CMO, and details about the presentation at the ASH Annual Meeting. This format—announcing significant clinical trial results and data presentation—is characteristic of an Earnings Release (ER) or a general announcement. Since it is a press release announcing clinical trial data rather than a formal regulatory filing (like 10-K or IR) or a transcript of a call, the most appropriate classification among the provided options is 'Earnings Release' (ER), as these releases often contain the most recent material operational/financial news, even if not strictly quarterly earnings. However, given the focus is purely on clinical trial data presentation, it could also be considered a Regulatory Filing (RNS) if ER is reserved strictly for financial performance reporting. Since the document is a detailed announcement of study results presented at a conference, and not a short notice of publication, it is more substantial than an RPA. Given the options, 'ER' is often used broadly for major company news announcements, but 'RNS' (Regulatory Filings/General Announcement) is a safer fallback for non-standard announcements. Since the content is a detailed announcement of clinical trial data, which is material information, and it is not a formal financial report, I will classify it as an Earnings Release (ER) as these often encompass major operational/clinical milestones, or RNS. Given the context of financial reporting databases, major clinical trial readouts are often grouped with ERs or IP/MDA. Since it is a press release announcing results, ER is the best fit for a major announcement, though RNS is a possibility. I will lean towards ER as it is a major announcement of company progress/potential product success. Q4 2024
2024-12-07 English
Communiqué de presse : ASH : le rilzabrutinib a apporté un bénéfice significatif aux patients atteints de TPI dans le cadre de la première étude de phase III positive consacrée à un inhibiteur de la B
Earnings Release Classification · 99% confidence The document is titled "Communiqué de presse" (Press Release) and details the positive results of the Phase III LUNA 3 study for the drug rilzabrutinib in treating Immune Thrombocytopenia (ITP). It explicitly states that these results were presented at the 66th Annual Meeting of the American Society of Hematology (ASH) and provides a detailed breakdown of the study data, expert quotes, and information about the drug and the disease. This format—a formal announcement of clinical trial results coinciding with a major medical conference presentation—is characteristic of an Earnings Release (ER) or a general announcement related to clinical data. Since it is a press release announcing key clinical trial results (Phase III data) and not a comprehensive periodic financial report (like 10-K or IR), the most appropriate classification is Earnings Release (ER), as these often include significant operational/clinical milestones alongside financial highlights, or sometimes serve as the primary vehicle for such announcements when no formal earnings report is due. Given the focus is entirely on clinical trial data presentation at a conference, it strongly aligns with the purpose of an ER or a major operational update. Since the definitions provided prioritize ER for initial financial result announcements, and this is a major data release, ER is the best fit among the options, although it is primarily clinical data. It is not a Call Transcript (CT) as it is a written release, nor is it a standard Investor Presentation (IP) which is usually slide-based. It is a formal announcement of results, fitting the ER category best for a non-financial report announcement. Q4 2024
2024-12-07 French
Press Release: Availability of the revised financial statements for Sanofi excluding Opella
Earnings Release Classification · 99% confidence The document is explicitly titled "Press Release" and announces the "Availability of the revised financial statements for Sanofi excluding Opella." It details that the revised financial data is now available on the company's website and mentions that the Q4 2024 results reflecting the new scope are expected to be published on January 30, 2025. Since the document itself is an announcement about the availability of financial data/reports rather than the comprehensive report (like 10-K or IR) or the initial highlights (ER), it fits the definition of a Report Publication Announcement (RPA). The document length (6300 chars) is substantial, but the core function is to announce the publication/availability of other documents/data, aligning best with RPA. Q4 2024
2024-12-06 English
Communiqué de presse : Mise en ligne des états financiers révisés de Sanofi hors Opella
Report Publication Announcement Classification · 99% confidence The document is titled "Communiqué de presse" (Press Release) and announces the availability of revised financial statements following a planned divestiture (Opella). It explicitly states that the revised financial data, which has been reviewed by auditors, is now available on the investor relations section of the website in a spreadsheet format ("dans un seul fichier tableur adapté"). It also mentions the upcoming publication date for the Q4 2024 results (January 30, 2025). Since the primary purpose of this short communication is to announce the publication/availability of financial data (which is provided in a spreadsheet format, suggesting supplementary data) and it is not the full financial report itself (10-K or IR), it fits best as a Report Publication Announcement (RPA) or potentially Financial Supplement Data (XLSX) if the linked spreadsheet is the main content. Given the text is an announcement *about* the availability of revised financial data/spreadsheet, RPA is the most accurate classification for the announcement itself, adhering to the 'MENU VS MEAL' rule. The mention of the spreadsheet format leans slightly towards XLSX, but the document structure is clearly an announcement of publication.
2024-12-06 French
Sanofi: Informations relatives au nombre de droits de vote et d'actions - Octobre 2024
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled "Informations relatives au nombre total de droits de vote et d'actions prévues par l'article L. 233-8 II du Code de commerce et l'article 223-16 du Règlement général de l'Autorité des Marchés Financiers". It provides a table detailing the total number of shares and voting rights as of a specific date (October 31, 2024). This content directly relates to the official disclosure of voting rights and share capital structure, which aligns perfectly with the definition of 'Declaration of Voting Results & Voting Rights Announcements' (DVA). It is not a full report (10-K, IR), an earnings release (ER), or a management presentation (IP).
2024-11-20 French

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.